A Randomized, Placebo-Controlled Trial of Pentoxifylline on Erythropoiesis-Stimulating Agent Hyporesponsiveness in Anemic Patients With CKD: The Handling Erythropoietin Resistance With Oxpentifylline (HERO) Trial

• Published in: American journal of kidney diseases Vol. 65; no. 1; pp. 49 - 57
• Main Authors: Johnson, David W., Pascoe, Elaine M., Badve, Sunil V., Dalziel, Kim, Cass, Alan, Clarke, Philip, Ferrari, Paolo, McDonald, Stephen P., Morrish, Alicia T., Pedagogos, Eugenie, Perkovic, Vlado, Reidlinger, Donna, Scaria, Anish, Walker, Rowan, Vergara, Liza A., Hawley, Carmel M.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.01.2015
• Subjects: Adult; Aged; Anemia; Anemia - blood; Anemia - drug therapy; Anemia - etiology; chronic kidney disease (CKD); Cost Savings; darbepoetin; dialysis; Double-Blind Method; Drug Monitoring - methods; Drug Resistance - drug effects; drug sensitivity; Drug Synergism; epoetin; Erythropoiesis - drug effects; erythropoiesis-stimulating agent (ESA); erythropoietin; Erythropoietin - administration & dosage; Erythropoietin - adverse effects; ESA hyporesponsiveness; ESA resistance index (ERI); Hematologic Agents - administration & dosage; Hematologic Agents - adverse effects; hemoglobin; Hemoglobins - analysis; Humans; Middle Aged; Nephrology; pentoxifylline; Pentoxifylline - administration & dosage; Pentoxifylline - adverse effects; Quality of Life; randomized controlled trial; Renal Insufficiency, Chronic - complications; Renal Insufficiency, Chronic - economics; Renal Insufficiency, Chronic - psychology; Vasodilator Agents - administration & dosage; Vasodilator Agents - adverse effects; dialysis; drug sensitivity; Anemia; ESA hyporesponsiveness; chronic kidney disease (CKD); hemoglobin; randomized controlled trial; erythropoiesis-stimulating agent (ESA); epoetin; pentoxifylline; darbepoetin; ESA resistance index (ERI); erythropoietin

Erythropoiesis-stimulating agent (ESA)-hyporesponsive anemia is common in chronic kidney disease (CKD). Pentoxifylline shows promise as a treatment for ESA-hyporesponsive anemia, but has not been rigorously evaluated. Multicenter, double-blind, randomized, controlled trial. 53 adult patients with CK...